Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system

被引:9
|
作者
Zhang, Ying [1 ]
Ran, Li [1 ]
Liang, Yongchao [1 ]
Zhang, Yanqiu [1 ]
An, Zhuoling [1 ]
机构
[1] Capital Med Univ, Beijing Chao Yang Hosp, Dept Pharm, Beijing, Peoples R China
关键词
pemigatinib; Food and Drug Administration adverse event reporting system; disproportionality analysis; real-word study; Advers drug events; PHASE-II; METASTATIC CHOLANGIOCARCINOMA; PATIENTS PTS; OPEN-LABEL; IN-VIVO; HYPOPHOSPHATEMIA; MULTICENTER; EXPRESSION; INHIBITORS; BGJ398;
D O I
10.3389/fphar.2023.1194545
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Cholangiocarcinoma (CCA) is a highly lethal and aggressive epithelial tumor of the hepatobiliary system. A poor prognosis, propensity for relapse, low chance of cure and survival are some of its hallmarks. Pemigatinib, the first targeted treatment for CCA in the United States, has been demonstrated to have a significant response rate and encouraging survival data in early-phase trials. The adverse events (AEs) of pemigatinib must also be determined.Objective: To understand more deeply the safety of pemigatinib in the real world through data-mining of the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).Methods: Disproportionality analysis was employed in a retrospective pharmacovigilance investigation to identify the AEs linked to pemigatinib use as signals. Data were collected between 1 January 2020 to 30 June 2022. Four data-mining methods (proportional reporting odds ratio; proportional reporting ratio; Bayesian confidence propagation neural networks of information components; empirical Bayes geometric means) were used to calculate disproportionality.Results: A total of 203 cases using pemigatinib as the prime-suspect medication were found in our search, which involved 99 preferred terms (PTs). Thirteen signals of pemigatinib-induced AEs in seven System Organ Classes were detected after confirming the four algorithms simultaneously. Nephrolithiasis was an unexpected significant AE not listed on the drug label found in our data-mining. Comparison of the differences between pemigatinib and platinum drugs in terms of 33 PTs revealed that 13 PTs also met the criteria of the four algorithms. Ten of these PTs were identical to those compared with all other drugs, in which (excluding a reduction in phosphorus in blood) other PT signal values were higher than those of all other drugs tested. However, comparison of the differences between pemigatinib and infigratinib in terms of the 33 PTs revealed no significant signals in each algorithm method.Conclusion: Some significant signals were detected between pemigatinib use and AEs. PTs with apparently strong signals and PTs not mentioned in the label should be taken seriously.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Hemolytic anemia following alectinib reported to the US Food and Drug Administration Adverse Event Reporting System
    Dores, Graca M.
    Nayernama, Afrouz
    Cheng, Connie
    Moureaud, Charlotte
    Jones, S. Christopher
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (04) : E129 - E132
  • [32] Cutaneous Toxicity Associated With Enfortumab Vedotin: A Real-Word Study Leveraging US Food and Drug Administration Adverse Event Reporting System
    Yang, Hui
    Yu, Xiaojia
    An, Zhuoling
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [33] Stimulated Reporting: The Impact of US Food and Drug Administration-Issued Alerts on the Adverse Event Reporting System (FAERS)
    Hoffman, Keith B.
    Demakas, Andrea R.
    Dimbil, Mo
    Tatonetti, Nicholas P.
    Erdman, Colin B.
    DRUG SAFETY, 2014, 37 (11) : 971 - 980
  • [34] Stimulated Reporting: The Impact of US Food and Drug Administration-Issued Alerts on the Adverse Event Reporting System (FAERS)
    Keith B. Hoffman
    Andrea R. Demakas
    Mo Dimbil
    Nicholas P. Tatonetti
    Colin B. Erdman
    Drug Safety, 2014, 37 : 971 - 980
  • [35] Safety of propofol use in children and adolescents: A disproportionality analysis of the Food and Drug Administration adverse event reporting system (FAERS)
    Li, Hailong
    Bo, Zhenyan
    Zhang, Lingli
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 334 - 335
  • [36] Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System
    Gaimari, Anna
    Fusaroli, Michele
    Raschi, Emanuel
    Baldin, Elisa
    Vignatelli, Luca
    Nonino, Francesco
    De Ponti, Fabrizio
    Mandrioli, Jessica
    Poluzzi, Elisabetta
    DRUG SAFETY, 2022, 45 (06) : 663 - 673
  • [37] Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System
    Anna Gaimari
    Michele Fusaroli
    Emanuel Raschi
    Elisa Baldin
    Luca Vignatelli
    Francesco Nonino
    Fabrizio De Ponti
    Jessica Mandrioli
    Elisabetta Poluzzi
    Drug Safety, 2022, 45 : 663 - 673
  • [38] Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database
    Tanni, Kaniz Afroz
    Truong, Cong Bang
    Almahasis, Sura
    Qian, Jingjing
    BIODRUGS, 2021, 35 (02) : 239 - 254
  • [39] Cardiovascular and Cerebrovascular Safety of Ranibizumab, Bevacizumab, and Aflibercept in Ocular Diseases: An Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) Database
    Zeng, Yanbin
    Guo, Xiaohui
    Xiao, Fengjiao
    Zhang, Haixia
    JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (08): : 909 - 917
  • [40] Adverse event reporting to US Food and Drug Administration and risk evaluation and mitigation strategies
    Thompson, Deborah L.
    Welsh, Kerry
    Alimchandani, Meghna
    MOLECULAR THERAPY, 2023, 31 (04) : 918 - 918